Annexins are considered as a family of calcium-dependent phospholipid-binding proteins. The structure of these proteins has some common features [1] ( Fig.1) . As a rule, annexins possess a variable amino-terminal domain and a carboxyl core domain. The last one is typically divided into four homologous domains (each of them is about 70 amino acid residues) and each of these domains consists of five α-helices. The amino-terminal domain contains sites for posttranslational modification and protein-protein interaction. It has to be noted that this domain provides the stability of the whole protein structure [2] . Posttranslational modifications in this region such as phosphorylation, acetylation or proteolysis make influence on the structure of key regions of the protein core even though they take place at the opposite side of the annexin molecule. The carboxyl core domain houses one or several calcium-binding motives (KGXGT-38 residues-D/E). Apart from the calcium-binding sites, in this domain there are also the sites for binding to heparin, F-actin and phospholipids (such as phosphatidyl serine and phosphatidylethanolamine). The annexins have been shown to take part in many processes: exocytosis, endocytosis, inhibition of blood coagulation, regulation of ion transport across membranes, membrane reorganization, vascular trafficking and redox regulation [3, 4] . In this review we mostly paid attention to those members of annexin family that can be found in the human hemostasis system. Normally annexins are not secreted from the living cells, and the appearance of these proteins in bloodstream can be conside red as a result of the cell degradation or apoptosis [5] . It is known that annexins lack the signal sequences that could direct them into the classical secretory pathway. However, for annexins A1, A2 and A5 the extracellular activity has been shown. Thus, annexin A5 is considered as an anticoagulant protein, annexin A2 as an endothelial receptor for plasminogen and tissue plasminogen activator (tPA), and annexin A1 as an anti-inflammatory agent [6] .
Annexin A1 and its role in inflammation
Annexin A1 has the longest history of reported extracellular activity. It was found in human serum at some pathological states such as myocardial infarction and experimental colitis [7, 8] . The role of annexin A1 in inflammation is related with glucocorti-coids as the main mechanism of glucocorticoids' anti-inflammatory effects is an increase of the synthesis and function of annexin A1 [9] . Glucocorticoids bind to the cytosolic glucocorticoid receptor, a type of nuclear receptor that is activated by the ligand binding. After the hormone binds to the receptor, the newly formed complex translocates itself into the cell nucleus, where it binds to the glucocorticoid response elements in the promoter region of annexin A1 gene resulting in stimulation of the gene expression [10] . Annexin A1 inhibits phospholipase A2. This is a calcium-dependent enzyme acting on phospholipids of membranes that releases arachidonic acid from the second carbon group of glycerol. Arachidonic acid is a precursor of prostaglandins and leucotriens playing the key role in the inflammatory reactions. On the other hand, annexin A1 may be considered as a regulator of leukocyte migration [11, 12] . As it is known, there are specific A1 receptors on the human neutrophils and monocytes [13] . They belong to the formyl peptide receptor (FRP) family of chemoattractant receptors. FRPs are the G-protein-coupled receptors, and they were identified by their ability to bind N-formyl peptides containing an N-terminal N-formylmethionine produced by the degradation of either bacterial or host cells (they can be released by the mitochondria). The formyl peptide receptor (FPR) signaling pathways include the following steps: G-protein dependent activation of phospholipase C, activation of the regulatory small GTP-ase, and activation of CD38, ectoenzyme of the membrane surface. The final result of the process is an increase in the cytoplasmic Ca 2+ level. The sustained increase of calcium is required for directed migration of the cells [14] . The sequences located in the unique N-terminal domain of annexin A1 specifically interact with the formyl peptide receptor on neutrophils, thereby eliciting the receptor-mediated intracellular responses leading to the inhibition of transendothelial migration.
Annexin A2 as a receptor on leukocytes and endothelial cells
Annexin A2 found on the surface of endothelial cells and leukocytes can function as a receptor for plasminogen and tPA acting as a positive modulator of the fibrinolytic cascade. The increased expression of annexin A2 on the surface of leukemic cells derived from the acute promyelocytic leukemia patients correlates with the clinical manifestation of bleeding [15] .
Endothelial cells are thought to play a key role in the intravascular plasmin generation, as they synthetize and secrete plasminogen activators (tPA and uPA) and their inhibitors (PAI-1) [16] . It is remarkable that on endothelial cells, annexin A2 is constitutively translocated to the cell surface within 16 hours of its biosynthesis where it may consist 5 % of the cellular protein pool [17] . Exogenous I 125 -labeled annexin A2 bound to endothelial cell surface with high affinity (Kd 49nM) in a calcium-dependent manner. This binding may be blocked by peptides mimicking the classical "annexin repeat" (KGXGT) [16] . Annexin A2 is thought to be a major membrane receptor of tPA on endothelium [18] . It has been shown that tPA, plasminogen and plasmin bind to annexin A2 through protein p11 with different affinity (Kd 0.68 µM, 0.11 µM and 75 nM respectively) [19] . There is a tight hydrophobic interaction between p11 and annexin A2. Complex p11-annexin A2 binds tPA, plasmin and plasminogen due to the C-terminal lysine residue of the p11 molecule [1] . The formed complex can provide generation of the extracellular plasmin (plasminogen is converted into plasmin by cleaving peptide bond between Arg 561 and Val 562 by tPA) [20] . However, the proposed profibrinolytic function of annexin A2 is somewhat controversial, as there are the data, that annexin A2 in complex with p11 can also inhibit the plasmin activity and fibrinolysis [21] .
Recently, it has been demonstrated that the tPAannexin A2 interaction may play a significant role during inflammation process (Fig.2) .
Under the stimulation of tPA, annexin A2 aggregates with β-2 integrin CD 11b, leading to the activation of integrin-linked kinase (ILK) pathway [22] . Thus, annexin A2 can transduce tPA signaling through its interaction with integrins. Annexin A2 mediates tPA-induced NF-kB activation in macrophages. In physiological status, the members of NFkB family (p50, p52, p65 and other) are retained in the cytoplasm by the specific inhibitor IkB. Upon activation, IkB becomes phosphorylated, which leads to its degradation and the release of NF-kB dimers into nuclei. It results in the subsequent DNA binding and transcription of the target proinflammatory genes. Blocking any step of this cascade (e.g. using annexin A2 antibodies) eliminates the tPA-induced NF-kB activation.
Annexin A5 as an anticoagulant factor and apoptosis marker
Annexin A5 was originally isolated from the human umbilical cord artery by virtue of its anticoagulant ac- tivity [23] . As it was mentioned above, all calciumbinding annexins are thought to be natural anticoagulants. It is known that the phosphatidyl serine (PS) exposure on the outer membrane is the characteristic of the activated platelets or endothelial cells [24] . PS facilitates the assembly and activation of the tenase and prothrombinase complexes [25] . The annexin A5 binding to PS results in formation of an anticoagulant shield on the cell membrane [5] .This shield is of great importance for placental cells as annexin A5 binds to the apical surface of placental syncytiotrophoblasts providing maintenance of normal blood flow through the placenta. The disruption of the shield leads to the development of antiphospholipid syndrome. As a result the apical surface of placenta becomes thrombogenic and patients with antiphospholipid syndrome suffer from recurrent pregnancy losses [26] . It has also been shown that extracellular as well as cytosolic annexin A5 binds to the disrupted site of injured plasma membrane as early as a few seconds after membrane wounding and promotes membrane resealing [27] . All these data raise the question of a role of annexin A5 in the protection and repair of membrane injuries in trophoblasts.
On the other hand, annexin A5 is the main annexin of human platelets [28] . Annexin A5 binds to platelets with high affinity (Kd 7nM) [29] . It was found that each platelet has approximately 5,000 sites to bind annexin A5. After thrombin stimulation, the amount of annexin-binding sites per platelet can reach 200,000. The treatment with phospholipase C or adding phospholipase preparations to the platelet mixture led to inhibition of annexin A5 binding [30] . Annexin A5 is also exposed on the apoptotic platelets [31] . During platelet apoptosis, the PS exposure occurs via the caspase and calpain activation, when platelets undergo a cellular death pathway leading to their clearance from the circulation by scavenger cells [32] . These events could be also induced in vitro by thrombin. It is remarkable, that the aging and stored platelets were also positive for PS [33] . However, it is necessary to carry out the analysis of other biomarkers to distinguish the platelet activation and apoptosis-mediated changes from each other [34] . So, annexin A5 can serve as a marker of activated or apoptotic platelets and its determination in blood and on the surface of blood cells or endothelium can be very important for the diagnosis and treatment of hemostasis disorders [35] .
Annexin A5 effect on plasminogen binding
In the presence of apoptotic factors, plasminogen considerably increases phosphatidyl serine exposure. This effect was shown for monocytes and neutrophils. The increased exposure of phosphatidyl serine is associated with the growing plasminogen binding to the cell surface [36] . This effect is explained by the histone H2B exposure on the surface of apoptotic monocytes. Histone H2B has different binding sites for phosphatidyl serine and plasminogen and can provide the efficient binding of both components with the cell surface. Annexin A5 competes with histone H2B for phosphatidyl serine binding and as a result plasminogen binding to cells is inhibited.
On the other hand, the platelet activation with thrombin led to an increased exposure of phosphatidyl serine in case of platelets and, as a result, elevated plasminogen binding was observed on the platelet surface [37] . The phosphatidyl serine exposure in these experiments was detected using annexin A5. It was found a special place on the platelet surface, socalled protruding "cap", where plasminogen [37] , thrombospondin and fibrinogen/fibrin were colocalized [38] . As this "cap" was also the localization place for factor XIIIa [39] , it was suggested that fibrin plays a special role in amplifying the plasminogen binding to annexin A5 bound platelets [37] .
However, we could also observe the plasminogen effect on the annexin A5 binding in case of activated platelets [40] . In our experiments the exogenous plasminogen preincubated with washed human platelets leads to the increased exposure of annexin A5 on the platelet surface after the thrombin stimulation. As there are no data about the formation of annexin A5-plasminogen complex, and histon H2b is not exposed on the platelet surface, the mechanism of the observed effect may be clarified only after series of further investigations.
Future perspective
Although numerous studies clearly indicate that extracellular annexins play an important role in the functioning of human organisms, there are still many gaps in our understanding of the molecular mechanisms underlying their action. The structural peculiarities of annexins may be very important in this case. As it was shown some annexins (A2 and A5) interact with carbohydrates, in particular glycosaminoglycans. These interactions are likely to come into play only for extracellular annexins but functional significance of this binding remains to be proven [41, 42] . On the other hand, there are some proposals for practical application of annexins in medical practice. It has been reported about diannexin, an annexin A5 homodimer that binds phosphatidyl serine with high affinity (0.6 nM) [43] . This new preparation may find practical application in medicine due to its ability to reduce the surface area coverage by platelets perfused with human blood and to inhibit in vivo the thrombus formation and fibrin deposition in the rat and rabbit models of arterial and venous thrombosis.
There are numerous reports about the agents constructed on the annexin base as apoptotic markers [44] [45] [46] . Elevated annexin V levels have been found in acute and chronic renal conditions [47] ; in patients with heart failure a high circulating annexin V level is likely to reflect peripheral organ damage [48] . Some annexins can be predicted as therapeutic agents. So, annexin V can be used in treatment of the patients with sickle cell disease [49] . There are some interesting reports concerning using annexin V as a potential marker in tumors [50, 51] and as a therapeutic agent for the patients with diffuse large B-cell lymphoma [52] .
However, future investigations are needed to clarify the precise way of the annexin turnover in human organism.
